Jinbo Shi

Dr. Jinbo Shi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Pancreas
Verified
Journal Article
Open access
BXBin Xu
Bin Xu
JSJinbo Shi
Jinbo Shi
WLWenjie Lu
Wenjie Lu
YWYulian Wu
Yulian Wu
XDXin Dong
Xin Dong
Objectives: The study aim to investigate whether elderly patients with resectable pancreatic ductal adenocarcinoma (PDAC) could benefit from postoperative chemotherapy. Methods: This study selects the data of PDAC patients who were diagnosed between 2004 and 2014 from the Surveillance, Epidemiology, and End Results program. Median overall survival (mOS) is determined by Kaplan-Meier survival curves. Multivariate logistic regression analysis and hazard ratio are employed to assess the association among potential prognostic factors. Propensity score matching evaluation is used to reduce bias. Results: In total, there are 11,865 PDAC patients selected from the Surveillance, Epidemiology, and End Results database. Elderly PDAC patients have poor prognoses compared with younger (mOS, 15 vs 21 months). The possible reason might be that the elderly patients are less likely to receive postoperative chemotherapy. After propensity score matching, it is found that, for those who receive postoperative chemotherapy, although the mOS of older group is not as good as that of the younger group (mOS, 20 vs 23 months; 18-month survival rate: 53.4% vs 61.3%), the mOS of older group prolonged by postoperative chemotherapy is similar to that of younger group (9 vs 9 months). Conclusions: Elderly PDAC patients (≥70 years) might benefit from the currently used postoperative chemotherapy regimens.

11 May 2026 in Research Square
Verified
Preprint
Open access
PDF file
JSJinbo Shi
Jinbo Shi
ZNZhongkai Ni
Zhongkai Ni
SHShifei Huang
Shifei Huang
XLXiaowen Li
Xiaowen Li
HHHai Huang
Hai Huang
The role of adjuvant chemotherapy in stage IA (T1N0M0) pancreatic cancer remains unclear. We evaluated its survival benefit using the SEER database (2010–2022). Among 727 patients with resected stage IA disease, propensity score matching generated 241 well-balanced pairs. Chemotherapy was associated with worse overall survival (log‑rank P = 0.019) and cancer‑specific survival (P = 0.006). Subgroup analyses by age, T stage, and grade showed no benefit. A causal forest model revealed a median individual treatment effect of –2.96 months (IQR: –4.05 to 2.33 months), indicating no clinically meaningful benefit for most patients. Cross‑validation failed to confirm reliable predictive performance. Adjuvant chemotherapy was not associated with improved survival in resected stage IA pancreatic cancer, challenging its routine use and supporting a more individualized approach. Prospective validation will require multi‑institutional collaboration due to disease rarity.